262 related articles for article (PubMed ID: 25740058)
1. The circadian gene CRY2 is associated with breast cancer aggressiveness possibly via epigenomic modifications.
Mao Y; Fu A; Hoffman AE; Jacobs DI; Jin M; Chen K; Zhu Y
Tumour Biol; 2015 May; 36(5):3533-9. PubMed ID: 25740058
[TBL] [Abstract][Full Text] [Related]
2. The core circadian gene Cryptochrome 2 influences breast cancer risk, possibly by mediating hormone signaling.
Hoffman AE; Zheng T; Yi CH; Stevens RG; Ba Y; Zhang Y; Leaderer D; Holford T; Hansen J; Zhu Y
Cancer Prev Res (Phila); 2010 Apr; 3(4):539-48. PubMed ID: 20233903
[TBL] [Abstract][Full Text] [Related]
3. Phenotypic effects of the circadian gene Cryptochrome 2 on cancer-related pathways.
Hoffman AE; Zheng T; Ba Y; Stevens RG; Yi CH; Leaderer D; Zhu Y
BMC Cancer; 2010 Mar; 10():110. PubMed ID: 20334671
[TBL] [Abstract][Full Text] [Related]
4. Exploring breast carcinogenesis through integrative genomics and epigenomics analyses.
Minning C; Mokhtar NM; Abdullah N; Muhammad R; Emran NA; Ali SA; Harun R; Jamal R
Int J Oncol; 2014 Nov; 45(5):1959-68. PubMed ID: 25175708
[TBL] [Abstract][Full Text] [Related]
5. Differential methylation hybridization profiling identifies involvement of STAT1-mediated pathways in breast cancer.
Kim JH; Kang HS; Kim TW; Kim SJ
Int J Oncol; 2011 Oct; 39(4):955-63. PubMed ID: 21674123
[TBL] [Abstract][Full Text] [Related]
6. Genome-wide methylation analysis identifies involvement of TNF-α mediated cancer pathways in prostate cancer.
Kim SJ; Kelly WK; Fu A; Haines K; Hoffman A; Zheng T; Zhu Y
Cancer Lett; 2011 Mar; 302(1):47-53. PubMed ID: 21237555
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic silencing of CREB3L1 by DNA methylation is associated with high-grade metastatic breast cancers with poor prognosis and is prevalent in triple negative breast cancers.
Ward AK; Mellor P; Smith SE; Kendall S; Just NA; Vizeacoumar FS; Sarker S; Phillips Z; Alvi R; Saxena A; Vizeacoumar FJ; Carlsen SA; Anderson DH
Breast Cancer Res; 2016 Jan; 18(1):12. PubMed ID: 26810754
[TBL] [Abstract][Full Text] [Related]
8. CRY2 is suppressed by FOXM1 mediated promoter hypermethylation in breast cancer.
Liu L; Shen H; Wang Y
Biochem Biophys Res Commun; 2017 Aug; 490(1):44-50. PubMed ID: 28579430
[TBL] [Abstract][Full Text] [Related]
9. Clock-cancer connection in non-Hodgkin's lymphoma: a genetic association study and pathway analysis of the circadian gene cryptochrome 2.
Hoffman AE; Zheng T; Stevens RG; Ba Y; Zhang Y; Leaderer D; Yi C; Holford TR; Zhu Y
Cancer Res; 2009 Apr; 69(8):3605-13. PubMed ID: 19318546
[TBL] [Abstract][Full Text] [Related]
10. DNA methylation pattern of the SLC25A43 gene in breast cancer.
Lindqvist BM; Farkas SA; Wingren S; Nilsson TK
Epigenetics; 2012 Mar; 7(3):300-6. PubMed ID: 22430806
[TBL] [Abstract][Full Text] [Related]
11. Methylome and transcriptome analyses reveal insights into the epigenetic basis for the good survival of hypomethylated ER-positive breast cancer subtype.
Chen XQ; Zhang F; Su QC; Zeng C; Xiao FH; Peng Y
Clin Epigenetics; 2020 Jan; 12(1):16. PubMed ID: 31959227
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic and genetic burden measures are associated with tumor characteristics in invasive breast carcinoma.
O'Sullivan DE; Johnson KC; Skinner L; Koestler DC; Christensen BC
Epigenetics; 2016 May; 11(5):344-53. PubMed ID: 27070496
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic silencing of the candidate tumor suppressor gene PROX1 in sporadic breast cancer.
Versmold B; Felsberg J; Mikeska T; Ehrentraut D; Köhler J; Hampl JA; Röhn G; Niederacher D; Betz B; Hellmich M; Pietsch T; Schmutzler RK; Waha A
Int J Cancer; 2007 Aug; 121(3):547-54. PubMed ID: 17415710
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic regulation of cancer stem cell genes in triple-negative breast cancer.
Kagara N; Huynh KT; Kuo C; Okano H; Sim MS; Elashoff D; Chong K; Giuliano AE; Hoon DS
Am J Pathol; 2012 Jul; 181(1):257-67. PubMed ID: 22626806
[TBL] [Abstract][Full Text] [Related]
15. Normal breast tissue DNA methylation differences at regulatory elements are associated with the cancer risk factor age.
Johnson KC; Houseman EA; King JE; Christensen BC
Breast Cancer Res; 2017 Jul; 19(1):81. PubMed ID: 28693600
[TBL] [Abstract][Full Text] [Related]
16. Interplay between promoter methylation and chromosomal loss in gene silencing at 3p11-p14 in cervical cancer.
Lando M; Fjeldbo CS; Wilting SM; C Snoek B; Aarnes EK; Forsberg MF; Kristensen GB; Steenbergen RD; Lyng H
Epigenetics; 2015; 10(10):970-80. PubMed ID: 26291246
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide methylation screen in low-grade breast cancer identifies novel epigenetically altered genes as potential biomarkers for tumor diagnosis.
Faryna M; Konermann C; Aulmann S; Bermejo JL; Brugger M; Diederichs S; Rom J; Weichenhan D; Claus R; Rehli M; Schirmacher P; Sinn HP; Plass C; Gerhauser C
FASEB J; 2012 Dec; 26(12):4937-50. PubMed ID: 22930747
[TBL] [Abstract][Full Text] [Related]
18. Deregulated expression of cryptochrome genes in human colorectal cancer.
Mazzoccoli G; Colangelo T; Panza A; Rubino R; De Cata A; Tiberio C; Valvano MR; Pazienza V; Merla G; Augello B; Trombetta D; Storlazzi CT; Macchia G; Gentile A; Tavano F; Vinciguerra M; Bisceglia G; Rosato V; Colantuoni V; Sabatino L; Piepoli A
Mol Cancer; 2016 Jan; 15():6. PubMed ID: 26768731
[TBL] [Abstract][Full Text] [Related]
19. Enrichment of CpG island shore region hypermethylation in epigenetic breast field cancerization.
Muse ME; Titus AJ; Salas LA; Wilkins OM; Mullen C; Gregory KJ; Schneider SS; Crisi GM; Jawale RM; Otis CN; Christensen BC; Arcaro KF
Epigenetics; 2020 Oct; 15(10):1093-1106. PubMed ID: 32255732
[TBL] [Abstract][Full Text] [Related]
20. Cryptochrome 2 (CRY2) Suppresses Proliferation and Migration and Regulates Clock Gene Network in Osteosarcoma Cells.
Yu Y; Li Y; Zhou L; Yang G; Wang M; Hong Y
Med Sci Monit; 2018 Jun; 24():3856-3862. PubMed ID: 29879092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
